Tesamorelin

Tesamorelin is an engineered peptide modelled on growth hormone-releasing hormone, an endogenous regulator of growth hormone release. It has been investigated for changes in intra-abdominal adipose tissue in people with HIV-related lipodystrophy, while wider metabolic applications require separate evaluation.

Growth hormone-releasing hormone participates in the endocrine control of growth hormone secretion. Growth hormone signalling influences tissue metabolism and the production of insulin-like growth factor 1 (IGF-1), linking this pathway to research on adipose tissue distribution.

Tesamorelin is designed to engage the GHRH signalling pathway and promote endogenous growth hormone release. Research described in the notes connects this hormonal response with possible changes in visceral adipose tissue and metabolic measures, but these downstream outcomes should not be treated as established benefits across populations.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 04 · Clinical evidence

Controlled clinical research supports specific, narrowly defined conclusions.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents tesamorelin as having been developed to address excess intra-abdominal fat associated with HIV-related lipodystrophy. It also discusses interest in broader changes in body composition and metabolism without supplying supporting study details. The guide characterises tolerability favourably while acknowledging local skin reactions, fluid accumulation, digestive symptoms and concerns associated with elevated IGF-1.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The extracted material does not establish the strength, durability or generalisability of the reported outcomes. Its broad metabolic claims lack defined endpoints and should not be extrapolated beyond the populations studied.

The guide reports possible local redness or swelling, fluid accumulation, nausea and abdominal discomfort; its favourable tolerability description does not establish safety for every individual. Increased IGF-1 warrants clinical assessment, particularly when there is a cancer history or another relevant endocrine concern. Safety data are limited in the supplied material, especially for broader applications, and this summary is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Tesamorelin visceral fat reduction”
• “Tesamorelin in HIV-associated lipodystrophy”
• “Tesamorelin peptide for metabolic syndromel”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN